Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (not Savara Inc.) on June 19, 2014. The filing details corporate governance actions taken on the date of the Company's 2014 Annual Meeting of Stockholders, including the election of directors, the approval of a new equity incentive plan, and the adoption of an executive incentive plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on governance and compensation structures. Key compensation-related figures include:
- Director Compensation: New director Howard C. Dittrich, M.D., receives an annual cash retainer of $20,000 (pro-rated for Q2 2014) and $1,000 per board meeting attended.
- Director Equity Grants: Dr. Dittrich was granted two stock options to purchase 46,609 shares each (total 93,218 shares) at an exercise price of $0.65 per share.
- Executive Incentive Targets (2014):
- CEO (Brian M. Culley): $202,500
- President/COO (Patrick L. Keran): $202,500
- CMO (Santosh J. Vetticaden): 35% of base salary
- CFO (Brandi L. Roberts): 30% of base salary
Material Changes Versus Prior Period
The filing outlines significant changes to the Company's equity and incentive frameworks compared to the prior "Existing Plan" (2013 Omnibus Incentive Plan):
- Share Availability: The new 2014 Omnibus Incentive Plan increases available shares for grants by 13,448,778 shares.
- Plan Expiration: Extended from June 19, 2023, to June 19, 2024.
- Fungible Ratio: Reduced from 1.5-to-1 to 1.2-to-1 for awards other than options and SARs.
- Automatic Exercise: The 2014 Plan introduces provisions for the automatic exercise of "in-the-money" options and SARs upon expiration, a feature absent in the prior plan.
- Section 162(m) Limits: Per-person limits for stock options/SARs increased to 4,000,000 shares (from 5,000,000 under the old plan for options, but the new plan standardizes limits and introduces a 2x multiplier for new hires in their first year).
Guidance, Outlook, and Risks
Management Commentary and Objectives: The 2014 Executive Incentive Plan ties executive compensation to specific corporate performance objectives, including:
- Progress in the Phase 3 EPIC study for MST-188 in sickle cell disease.
- Development of MST-188 for other indications (heart failure, adjunctive therapy to thrombolytics).
- Clinical development of AIR001.
- Chemistry, manufacturing, and controls (CMC) initiatives.
- Intellectual property initiatives.
- Maintaining specified levels of capital.
Risks and Contingencies: The Compensation Committee retains absolute discretion to abolish the Incentive Plan or alter terms without notice. Incentive awards are contingent on continuous employment through the payment date (on or before March 14, 2015). The filing notes that the Company's stock price was $0.65 on June 19, 2014.
Investor Verification Checklist
- Verify the exact number of shares authorized under the 2014 Omnibus Incentive Plan and the total dilution impact.
- Confirm the specific "specified levels of capital" required to meet executive performance objectives.
- Review the definitive proxy statement (Schedule 14A filed April 29, 2014) for the full text of the 2014 Plan and detailed voting results.
- Monitor the progress of the Phase 3 EPIC study for MST-188 as a primary driver of executive compensation.
- Check subsequent filings for any adjustments to the 2014 Executive Incentive Plan objectives due to strategic changes.